Digest Network Come funziona
Network
/
Società
Re
Non verificato

Response Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaFitnessIndustriaSalute

4 comunicati stampa

Guarda tutti i comunicati
05/03/2026
Industria
Biotecnologia
Farmaceutica
Sanità
Attrezzature medico-sanitarie
Salute
Fitness
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management
Fonte
Response Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/08/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Fitness
Medicina - Varie
Industria
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
Fonte
Response Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/02/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
Fonte
Response Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/10/2024
Fiere
Industria
Salute
Fitness
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
Fonte
Response Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0